[{"orgOrder":0,"company":"Pediatric Brain Tumor Consortium","sponsor":"Treovir, LLC | National Cancer Institute | American Lebanese Syrian Associated Charities","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"G207","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Pediatric Brain Tumor Consortium","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pediatric Brain Tumor Consortium \/ Treovir, LLC | National Cancer Institute | American Lebanese Syrian Associated Charities","highestDevelopmentStatusID":"8","companyTruncated":"Pediatric Brain Tumor Consortium \/ Treovir, LLC | National Cancer Institute | American Lebanese Syrian Associated Charities"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Cannonball Kids' Cancer Foundation | Treovir, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"G207","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Cannonball Kids' Cancer Foundation | Treovir, Inc","highestDevelopmentStatusID":"6","companyTruncated":"MD Anderson Cancer Center \/ Cannonball Kids' Cancer Foundation | Treovir, Inc"},{"orgOrder":0,"company":"Matica Biotechnology","sponsor":"Treovir","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Partnership","leadProduct":"G207","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Matica Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Matica Biotechnology \/ Treovir","highestDevelopmentStatusID":"8","companyTruncated":"Matica Biotechnology \/ Treovir"}]

Find Clinical Drug Pipeline Developments & Deals for G207

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Neuroscience
                          Not Confirmed
                          Neuroscience
                          Not Confirmed

                          Details : The collaboration aims to advance G207 HSV-based oncolytic therapy for pediatric patients with brain and other neurological cancers.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          December 04, 2024

                          Lead Product(s) : G207

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Treovir

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          02

                          Pediatric Brain Tumor Consortium

                          Country arrow
                          Neuroscience
                          Not Confirmed

                          Pediatric Brain Tumor Consortium

                          Country arrow
                          Neuroscience
                          Not Confirmed

                          Lead Product(s) : G207

                          Therapeutic Area : Oncology

                          Study Phase : Phase II

                          Sponsor : Treovir, LLC | National Cancer Institute | American Lebanese Syrian Associated Charities

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : G207 is a Other Large Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 23, 2020

                          Lead Product(s) : G207

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Treovir, LLC | National Cancer Institute | American Lebanese Syrian Associated Charities

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          MD Anderson Cancer Center

                          Country arrow
                          Neuroscience
                          Not Confirmed

                          MD Anderson Cancer Center

                          Country arrow
                          Neuroscience
                          Not Confirmed

                          Details : G207 is a Other Large Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Brain Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 11, 2019

                          Lead Product(s) : G207

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Cannonball Kids' Cancer Foundation | Treovir, Inc

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank